Glaukos price target raised to $85 from $80 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Glaukos (GKOS) to $85 from $80 and keeps an Overweight rating on the shares. The firm’s survey of 25 ophthalmologists indicates the micro invasive glaucoma surgery market continues to gain broader adoption in the glaucoma treatment paradigm. The survey indicates Glaukos should maintain its leading position while Sight Sciences (SGHT) should see some share loss over the next several years, the analyst tells investors in a research note.